七彩化學(300758.SZ):擬以1.45億元受讓紹興上虞新利化工29%股權
格隆匯5月24日丨七彩化學(300758.SZ)公佈,公司擬以自有資金人民幣1.45億元受讓陳建新持有的公司控股子公司紹興上虞新利化工有限公司(“上虞新利”)29%股權,此次交易完成後公司將持有上虞新利80%股權。
此次公司收購,有利於提升公司管理效率,降低管理成本,增強公司在高性能有機顏料板塊,特別是苯並咪唑酮系列有機顏料領域的全球競爭優勢與市場地位。此次交易不會導致公司合併報表範圍發生變化,不會對公司的財務狀況和未來的經營成果造成重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.